Guardant Health, Inc. (NASDAQ:GH - Get Free Report) CEO Amirali Talasaz sold 1,680 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $50.00, for a total value of $84,000.00. Following the transaction, the chief executive officer now owns 2,187,060 shares of the company's stock, valued at $109,353,000. This trade represents a 0.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Amirali Talasaz also recently made the following trade(s):
- On Monday, June 9th, Amirali Talasaz sold 77,853 shares of Guardant Health stock. The stock was sold at an average price of $50.09, for a total value of $3,899,656.77.
- On Friday, June 6th, Amirali Talasaz sold 39,751 shares of Guardant Health stock. The stock was sold at an average price of $50.07, for a total value of $1,990,332.57.
- On Thursday, May 1st, Amirali Talasaz sold 106,784 shares of Guardant Health stock. The stock was sold at an average price of $49.01, for a total value of $5,233,483.84.
Guardant Health Price Performance
Shares of GH stock traded down $0.01 on Thursday, reaching $49.02. 1,250,531 shares of the stock were exchanged, compared to its average volume of 2,124,938. The stock has a market cap of $6.07 billion, a PE ratio of -13.77 and a beta of 1.37. Guardant Health, Inc. has a one year low of $20.14 and a one year high of $52.92. The stock has a 50 day moving average price of $43.53 and a 200 day moving average price of $41.45.
Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.08. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The company had revenue of $203.47 million during the quarter, compared to the consensus estimate of $189.91 million. During the same quarter in the previous year, the company posted ($0.46) earnings per share. The firm's quarterly revenue was up 20.8% on a year-over-year basis. On average, research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Guardant Health
Institutional investors have recently made changes to their positions in the stock. SVB Wealth LLC acquired a new stake in shares of Guardant Health during the first quarter worth $54,000. SBI Securities Co. Ltd. acquired a new stake in shares of Guardant Health during the fourth quarter worth $43,000. Kimelman & Baird LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth $58,000. NewEdge Advisors LLC grew its stake in Guardant Health by 13.5% in the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after acquiring an additional 230 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Guardant Health in the fourth quarter valued at about $61,000. 92.60% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research firms recently commented on GH. UBS Group raised their target price on Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Barclays lifted their price objective on Guardant Health from $55.00 to $60.00 and gave the company an "overweight" rating in a research report on Thursday, May 1st. Guggenheim reiterated a "buy" rating and issued a $56.00 price objective on shares of Guardant Health in a research report on Monday, February 24th. Piper Sandler reiterated an "overweight" rating and issued a $60.00 price objective (up previously from $50.00) on shares of Guardant Health in a research report on Tuesday, May 6th. Finally, Morgan Stanley lifted their price objective on Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research report on Thursday, March 6th. Twenty equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Guardant Health presently has an average rating of "Buy" and a consensus target price of $53.29.
View Our Latest Report on GH
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Read More
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
